Minerva Neurosciences Files Q1 2025 10-Q
Ticker: NERV · Form: 10-Q · Filed: May 13, 2025 · CIK: 1598646
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
Minerva Neurosciences Q1 2025 10-Q filed. Focus on Seltorexant & financials.
AI Summary
Minerva Neurosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary focus is on the development of pharmaceutical preparations, with key products like Seltorexant mentioned. Financial details and operational segments, including staff-related expenses and drug product material costs, are reported for the first quarter of 2025.
Why It Matters
This filing provides insight into Minerva's financial health and operational progress in the first quarter of 2025, crucial for investors tracking the pharmaceutical development pipeline.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Minerva Neurosciences faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q1 2025 — Reporting Period (First quarter financial and operational data)
- 2025-03-31 — As of Date (Specific date for financial reporting)
Key Players & Entities
- Minerva Neurosciences, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- Seltorexant (drug) — Key product mentioned
- Royalty Pharma (company) — Associated entity
- Waltham, MA (location) — Company headquarters
FAQ
What is the primary business of Minerva Neurosciences, Inc. as indicated in this filing?
Minerva Neurosciences, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].
What is the reporting period for this 10-Q filing?
The conformed period of report is for the quarter ending March 31, 2025.
Which specific drug product is mentioned in relation to Minerva Neurosciences?
Seltorexant is mentioned as a key product.
Where is Minerva Neurosciences, Inc. located?
The company's business and mail address is 1601 Trapelo Road, Suite 286, Waltham, MA 02451.
What are some of the operational segments or cost categories reported?
The filing mentions Staff Related Expenses and Drug Product Material Expenses and Associated Costs within Operating Segments.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Minerva Neurosciences, Inc. (NERV).